Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sweeping FDA Changes Could Have “Disastrous Consequences” For Biotech Investment

Executive Summary

Lowering the bar on drug approval standards would create a challenging environment for biotech investors, warned Jonathan Leff, a partner at the health care investment firm Deerfield, during the BIO CEO & Investor Conference.

You may also be interested in...



Medicare Price Negotiations: HHS Nominee Suggests Adapting Part D 'Learnings' To Part B

Alex Azar talks about price negotiation in Medicare Part B, whether his biopharma industry ties would influence his decisions as head of HHS, insulin price increases and importation during the first of his confirmation hearings.

Trump’s Tweets On Drug Prices; Industry Says “Huh?”

US President targeted drug prices again on Twitter, and later in the day House Democratic Rep. Elijah Cummings announced a meeting with Trump March 8 to discuss lowering drug prices.

US FDA Commissioner Search: Pharma’s Preferred Candidate Is Gottlieb

Analyst poll of 53 drug companies indicates broad support for Scott Gottlieb compared to three other known candidates for FDA Commissioner.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC098237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel